Figure 2 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma

作者：Hazem Abdullah, In Hwa Um, Grant D. Stewart, Chang Wook Jeong, Cheol Kwak, Kyung Chul Moon, Alexander Laird, Eleni Frangou, Tim Eisen, Angela Meade, David J. Harrison · 年份：2026 · DOI：10.1158/2767-9764.32702082 · 研究领域：Renal cell carcinoma treatment、Multiple and Secondary Primary Cancers、Bladder and Urothelial Cancer Treatments

<p>P21<sup>+</sup>/MCM2<sup>−</sup> cell content improves risk stratification in intermediate-risk ccRCC. Kaplan–Meier survival analysis in the SORCE training cohort (<i>n</i> = 63) shows that patients with ≤2% P21<sup>+</sup>/MCM2<sup>−</sup> cells experienced significantly higher relapse rates than those with >2% (<i>P</i> < 0.001) within 142 months. In contrast, stratification by the raw LS (LS 3–5) demonstrated a trend that was not statistically significant (<i>P</i> = 0.21). Box-and-whisker plots reveal overlapping distributions of P21<sup>+</sup>/MCM2<sup>−</sup> cell percentages across LS subgroups. In the Korean validation cohort (<i>n</i> = 71), the same 2% threshold also significantly stratified outcomes (<i>P</i> = 0.005) within 195 months.</p>